Percutaneous complete revascularization strategies using sirolimus-eluting biodegradable polymer-coated stents in patients presenting with acute coronary syndrome and multivessel disease: Rationale and design of the BIOVASC trial - 25/08/20
, Nicolas M. Van Mieghem, MD PhD a, Johan Bennett, MD PhD b, Manel Sabate, MD PhD c, Giovanni Esposito, MD PhD d, Rutger J. van Bommel, MD PhD e, Joost Daemen, MD PhD a, Matthias Vrolix, MD PhD f, Paul A. Cummins, RN a, Mattie J. Lenzen, PhD a, Eric Boersma, MD PhD a, Felix Zijlstra, MD PhD a, Roberto Diletti, MD PhD aon Behalf of the BioVasc Trial Investigators
Abstract |
Background |
Complete revascularization in patients with an acute coronary syndrome and multivessel disease is superior compared to culprit-only treatment. However, it is unknown whether direct complete or staged complete revascularization should be pursued.
Methods |
The BIOVASC study is an investigator-initiated, prospective, multicenter, randomized, 2-arm, international, open-label, noninferiority trial. We will randomize 1,525 patients 1:1 to immediate complete revascularization (experimental arm) or culprit-only plus staged complete revascularization (control arm). Patients will be enrolled in approximately 30 sites in Belgium, Italy, the Netherlands, and Spain. The primary end point is a composite of all-cause mortality, nonfatal myocardial infarction, any unplanned ischemia-driven revascularization (excluding staged procedures in the control arm at the predetermined time), and cerebrovascular events (MACCE) at 1 year post index procedure.
Conclusions |
The BIOVASC study aims to further refine the treatment algorithm for acute coronary syndrome patients with multivessel disease in terms of optimal timing for complete revascularization (Clinicaltrials.gov NCT03621501).
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 227
P. 111-117 - settembre 2020 Ritorno al numero
Articolo precedente
- Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial
- Rodrigo Bruno Biagioni, Renato Delascio Lopes, Leandro Barile Agati, Roberto Sacilotto, Nelson Wolosker, Marcone Lima Sobreira, Bruno Leonardo de Freitas Soares, Edwaldo Edner Joviliano, Walkiria Hueb Bernardi, Valter Castelli Junior, Roberto Augusto Caffaro, Alexandre Fioranelli, Bonno Van Bellen, Ivan Benaduce Casella, Ronald José Ribeiro Fidelis, Ronald Luiz Gomes Flumignan, Anthony James Comerota, Eduardo Ramacciotti
- The utility of risk scores when evaluating for acute myocardial infarction using high-sensitivity cardiac troponin I
- Joseph Gibbs, Christopher deFilippi, Frank Peacock, Simon Mahler, Richard Nowak, Robert Christenson, Fred Apple, Gordon Jacobsen, James McCord
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?